Kiel Simone, Negnal Martha, Stracke Sylvia, Fleig Susanne, Kuhlmann Martin K, Chenot Jean-François
Department of General Practice, Greifswald University Medical Center, Greifswald, Germany; Department of Internal Medicine A, Greifswald University Medical Center, Greifswald, Germany; Department of Renal and Hypertensive Disease, Rheumatologic and Immunologic Diseases, Aachen University Hospital, Aachen, Germany; Department of Internal Medicine - Nephrology, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
Dtsch Arztebl Int. 2025 Jan 24;122(2):49-54. doi: 10.3238/arztebl.m2024.0230.
Chronic kidney disease (CKD) is common in the German adult population, with a prevalence of 10%. This guideline, updated on the basis of current scientific evidence, contains recommendations for the management of CKD in general practice.
The updated guideline is based on a review and assessment of source guidelines and systematic reviews concerning individual questions. The recommendations were agreed upon in a moderated two-stage nominal group process by the mandate holders of the participating specialist societies, along with patient representatives.
The risk of progression to renal failure requiring renal replacement therapy should be assessed with a risk score. Assessing this risk and determining the indication for treatment with SGLT2 inhibitors both require measurement of the urinary albumin-tocreatinine ratio. Pharmacotherapy is not recommended for asymptomatic hyperuricemia. An initial ultras - onographic examination of the kidneys and urogenital system is now recommended for all patients. The vaccination recommendations that differ for people with CKD have been integrated into the guideline.
The risk assessment of CKD and the treatment options have been expanded. The updated guideline can improve primary care for patients with CKD and the selection of patients for interdisciplinary care.
慢性肾脏病(CKD)在德国成年人群中很常见,患病率为10%。本指南基于当前科学证据进行更新,包含了全科医疗中CKD管理的建议。
更新后的指南基于对有关各个问题的源指南和系统评价的回顾与评估。建议由参与的专科协会的授权代表以及患者代表在一个经过主持的两阶段名义小组过程中达成一致。
应使用风险评分评估进展至需要肾脏替代治疗的肾衰竭风险。评估此风险以及确定使用SGLT2抑制剂治疗的指征均需要测量尿白蛋白与肌酐比值。不建议对无症状高尿酸血症进行药物治疗。现在建议对所有患者进行肾脏和泌尿生殖系统的初次超声检查。针对CKD患者不同的疫苗接种建议已纳入指南。
CKD的风险评估和治疗选择已得到扩展。更新后的指南可改善CKD患者的初级保健以及跨学科护理患者的选择。